Pfizer takeover could delay drug development, says Astra chief


AstraZeneca Chief Executive Pascal Soriot: "The risk associated with any large merger is disruption"

Related Stories

The chief executive of AstraZeneca has warned that new drug development could be hit if it were taken over by Pfizer.

Pascal Soriot told MPs that a takeover would create huge disruption and distraction as scientists worried about their futures rather than development.

However, Business Secretary Vince Cable later told the Business Committee that blocking a bid could be "tricky".

The committee is taking evidence on the proposed takeover amid worries about the damage it could do to UK interests.

Earlier, Pfizer's chief Ian Read told the MPs that his company was not a ruthless cost-cutter, and said the drugmaker acted with "integrity".

He repeated assurances that Pfizer would protect jobs and investment, but admitted that a merger would mean a reduction in the combined companies' spending on research and development.


Even though no formal offer from US-based Pfizer has been tabled, the proposed £63bn-plus takeover has generated huge controversy. The Commons Science Committee will hold its own hearing on Wednesday.

Mr Soriot told the Business Committee that the uncertainty created by a takeover could undermine some of AstraZeneca's work.

Start Quote

We are a highly ethical company. Pfizer is a company that keeps its promises”

End Quote Ian Read Chief executive, Pfizer

"Any distractions on work we are doing now could run the risk of delaying our drugs pipeline," he said. "From the lab to the patient takes many years.

"What will we tell the person whose father died from lung cancer because one of our medicines was delayed because our companies were involved in saving taxes or saving costs?

"It is logical to assume that a merger like this could mean substantial cost savings, and cost savings could mean job losses," he said.

Mr Soriot said the re-domiciling of the newly-merged company to the UK - which Pfizer has said would still see its headquarters remain in New York - would cause "substantial controversy", likely to result in delays.

However, he said that it would be the board of Astra's duty to consider a formal offer from Pfizer, despite rebuffing the US drugmaker's approaches so far.

Chief executive of Pfizer Ian Read: "I think the commitment of 20% of a global company's R&D in the UK is an unprecedented commitment"

"It's impossible to say we would never accept any offer," he told a committee. "We are very well aware of our fiduciary duty."

Limited powers

However, despite demands that the government should either block the bid or secure legal guarantees on jobs and investment, Mr Cable told the committee that intervention was "tricky".

The UK has public interest laws governing certain takeovers, such as those involving defence and media interests, but not for science.

Mr Cable said: "The framework which we have under the act, as you know, confines the public interest test quite narrowly and, of course, all of that takes place within the framework of European merger law."

For anyone in the pharmaceutical industry, the Holy Grail is the discovery of what they call a new "molecule", a cleverly-designed compound that proves effective as a treatment.

But achieving this is fiendishly complicated - getting approval has become hugely expensive and success is far from guaranteed.

AstraZeneca itself has a long history of developing new molecules to tackle everything from high blood pressure to breast cancer and the UK scientific community is rightly proud of that.

But less obvious amid the current war of words is that four of the company's most promising drugs are in its hands, not because of homegrown research, but because AstraZeneca acquired them when it bought a US firm called MedImmune.

One of these drugs is MEDI4736, not a name that trips off the tongue, but this molecule, designed to fight lung cancer, will soon enter the final phase of clinical trials.

So if Pfizer's takeover is successful, MEDI4736 will have yet another new owner.

No surprise, the staff of MedImmune - and the politicians supporting them in Maryland - are as worried about the implications of the Pfizer bid as AstraZeneca's people are here in the UK.

The business secretary refused to be drawn on the precise legal and financial mechanisms that could make Pfizer's assurances binding. He said he would "rather not expose" the government's thinking on that "in too much detail".

But he accepted that the government faced a "dilemma" between being open to the benefits of foreign investment and protecting wider national interests.

In response, Labour's shadow business secretary, Chuka Umunna, said he was still to be convinced that an acquisition would be good for the UK.

"I think what we heard at the hearing today reinforces the grave concerns we have about this deal and confirms many of the worst fears of many in the business and science community in the UK," he said.

"What do we know? [Pfizer] confirmed that they will be cutting jobs, they've confirmed that there will be a cut in the spending of the combined merged entity, they've confirmed that the business, AstraZeneca, will be split up, and they haven't ruled out selling off parts of it in the future."

And he pointed to AstraZeneca's assertion that the distraction of any deal could potentially inhibit the production of life-saving drugs.

But business body the Institute of Directors, said "we should be alive to the consequences of mounting a British Inquisition for those who wish to do business in what is supposed to be an open economy".

"If our politicians really want to whip up a storm around this issue, they'd be better off scrutinising the role of institutional investors in the whole process," added the body's director general Simon Walker.

"In particular, the asset managers and asset owners that control so many of AstraZeneca's shares."

Vince Cable says Pfizer faces "hurdles" before the takeover becomes binding

Earlier, Mr Read mounted a strong defence of Pfizer's record, rejecting complaints that it had a poor track record on maintaining jobs and investments, both in the UK and elsewhere.

Adrian Bailey, chairman of the Business Committee, asked Mr Read to respond to claims that Pfizer was like a "praying mantis" and a "shark that needs feeding".

Mr Read said he was "very proud" of his 35 years at the firm, describing it as a "company of high integrity focused on patients and delivering drugs to patients".

He said he was not concerned about an attack on the company by Swedish Prime Minister Fredrik Reinfeldt, who referred to "negative experiences" after Pfizer took over Pharmacia.

Mr Read said the comments were based on a "misunderstanding of the facts" over strategy and a promise to build a factory only if a product got regulatory approval. "Having set the facts right, I'm not concerned" by the comments, he said.

He added that a merged Pfizer-Astra would mean research expenditure would be lower than that of the two separate companies. This, he said, was because one of the drivers of the proposed deal was to increase efficiency in order to keep both firms competitive in an increasingly tough marketplace.

"Our commitment is to base 20% of our global research and development in the UK," he said. But without more due diligence on AstraZeneca's books "I can't tell you today how many people we are going to have in R&D," he added.

But the final jobs number would be "substantial", Mr Read promised. "I have not seen AstraZeneca's books. Some things are sight-unseen. But the numbers will be substantial... We are a highly ethical company. Pfizer is a company that keeps its promises."

Pfizer logo Pfizer has outlined its takeover proposals to AstraZeneca's shareholders

Committee member Mike Crockart asked why the UK Government should support a Pfizer bid, when "you have a reputation of being ruthless cost-cutters, and that seems to be borne out by what you have said today".

Mr Read replied that the takeover was "an opportunity to domicile the largest pharmaceutical company in the world, to bring the strength of the combined portfolios and to bring our financial strength into the UK and globally.

"I think it will strengthen the scientific base in the UK, a company our size making these sorts of commitments."

'Not long enough'

Before the committee hearing, the President of the Royal Society, Prof Sir Paul Nurse, told the BBC that Pfizer's five-year commitment to maintain research and jobs was "vague" and insufficient.

Sir Paul, who has submitted written evidence to the committee, said: "Research is a long-term business. I have researched for 40 years of my life. I know that five years is not long enough term to be committed to.

"They need to look at a 10-year horizon at least if they are actually going to make an important impact on this area and produce the medicines that will help people."

On Tuesday, Pfizer turned up the pressure on AstraZeneca by outlining its takeover proposals to Astra's shareholders.

Pfizer laid out the "strong strategic rationale" of the £63bn takeover plan.

Astra responded by calling Pfizer's takeover plan an "opportunistic attempt" to buy the company for a price that did not reflect the value of its "exciting pipeline" of new drugs.

Any deal would be the largest foreign takeover of a UK firm to date, but the proposal has revived memories of when US food giant Kraft abandoned jobs pledges after it bought Cadbury.

graphic about company size

More on This Story

Related Stories


This entry is now closed for comments

Jump to comments pagination
  • rate this

    Comment number 683.

    I worked for a company that merged with another. It was a complete disaster. I totally appreciate what the CEO of AstraZeneca was saying about disruption to the business.

  • rate this

    Comment number 660.

    My guess is that a large proportion of the people in this country are stakeholders in AZ through pension and other savings schemes. So they all have a valid opinion. Do they want to see R&D (=skilled workers) possibly move from this country and fewer companies (=less competition) supplying drugs to the NHS? Capitalism needs to benefit the whole country not just a single company.

  • rate this

    Comment number 624.

    It is obvious from some comments that the sole criteria for a takeover is making a quick buck. When UK no longer makes anything of significance where will investors go? Will major retail and insurance produce enough profit to suit more investors? If the purpose of investment is a quick buck rather than any sense of a long term strategy then the future for UK business is bleak.

  • rate this

    Comment number 105.

    there's a huge contradiction from the left on this. The left generally hate big business and hate pharmaceutical companies who they see as profiting from sick people. fair enough. but then you cant complain when the industry is driven down a path where R&D costs so much and new medicines don't get adopted by the NHS. job losses / mergers are inevitable

  • rate this

    Comment number 62.

    Either so many British businesses are badly mismanaged & unfit to survive, meaining takeovers are inevitable, or we have worthwhile industries needing proper managment & investment. The latter means there are still viable industries = proper employment for Brits, or the UK just goes to the wall & there's nothing left but shop work & fruit & veg picking. You choose.


Comments 5 of 10


More Business stories


BBC Business Live

    UK MORTGAGES 09:33:

    The Bank of England says British mortgage approvals fell slightly in July compared with the previous month, to 66,569. In January, the measure reached 76,000, but has been wavering as the housing market shows some signs of cooling.

    MARKET REPORT 09:26:

    The major European stock markets have had a muted start this morning.

    • The FTSE 100 is down 0.12% at 6811.88
    • The Dax is up 0.02% at 9472.17
    • The Cac 40 is down 0.12% at 4375.75

    BAE Systems is the biggest winner in London, up almost 3%, while Morrison Supermarkets has dropped 2.25%.

    ISLAND FLING 09:11:

    Some conferences are more appealing than others. The third UN Conference on Small Island Developing States begins in Apia, Samoa today. Some 50 countries are invited, and the agenda covers a wide-range of topics, including sustainable energy, water and sanitation, and biodiversity.

    Via Twitter Jamie McGeever, chief markets correspondent for Europe, Reuters

    tweets: "Italian manufacturing sector contracts for first time in over a year. PMI falls to 49.8 in Aug from 51.9 in July, expected 50.8."


    Perform Group, which owns the Omnisport sport news agency, rose 26% to 256.7 pence in London after Access Industries Group said it would buy the company. It already owns 42.5%.


    South Korean giant Samsung Group is to become even bigger, Bloomberg reports, after merging its shipbuilding and engineering units. Shares in both firms rose as a result of the announcement.


    Ecuador says its new digital currency will begin circulating in December. The electronic money will be the first backed by a central bank, and will work alongside the country's current currency - the US dollar. The president says it will help poorer people gain access to banking.

    Microsoft China

    The clock is ticking for Microsoft in China. Competition authorities have given the firm 20 days to reply to questions over the compatibility of some of its software, Reuters reports. Microsoft is one of several foreign companies that have come under scrutiny in the country in recent weeks.


    The Financial Times leads with Vladimir Putin's call for talks on "statehood" for south-east Ukraine. The paper calls it a provocative comment, which will heighten fears that Moscow is seeking partition for Ukraine. The Daily Telegraph says David Cameron and Barack Obama are to respond to the Russian president by urging NATO allies to increase defence spending. In a leader article the paper also recommends fresh sanctions.


    Berkeley Group, the home builder, is having its annual meeting today. The firm is "well positioned to continue to invest in the business and deliver returns to shareholders. Earnings this year are anticipated to be in line with current market expectations," chairman Tony Pidgley will say.

    KIER CONTRACT 07:23:

    Kier Group, the builder, says it is the preferred bidder to design and build a new £50m residential tower in London. The company says it will "design and construct 224 luxury apartments arranged in four blocks".

    GOING SOUTH 07:11:
    St Andrews

    The Guardian reports that Scotland's top universities are bracing themselves for a "brain drain" of their most talented scientists if there's a "yes" vote for independence. The paper says senior figures believe Scotland's best known universities would lose access to billions of pounds of funding - the subjects most at risk are said to include advanced computing and genetic research. However a source close to the Scottish government says the concerns are misplaced and research funding will be maintained.

    CUBAN IMPORTS 06:57:

    New rules are coming into force in Cuba, limiting the amount of goods people can take into the country in their luggage. For example, Cubans will be allowed only 10 kilos of detergent rather than 40, 24 bras rather than 48, and just two flat screen televisions. Many Cubans see the new restrictions as throttling one of the few sources of high-quality consumer goods.

    RAC LISTING 06:47: Radio 5 live
    RAC rescue vehicle

    Holly Cook, of Morningstar, was on 5 live too, talking about the car breakdown specialists RAC, who are said to be considering a stock market flotation. How come? It shows "more confidence in the market" and may be seen as a good investment as its business is easily understood, she says.

    FINANCE LITERACY 06:41: Radio 5 live

    Tracey Bleakley adds that the first rule of money management is "knowing the difference between something you need and something you want." Think about that in the lunch queue.

    FINANCE LITERACY 06:35: Radio 5 live

    Tracey Bleakley, chief executive of the Personal Finance Education Group is talking about the government's new plan to provide education on financial planning. "We've all got to talk about it," she says, adding that children could educate their parents. That way people can see through "the marketing" that lots of debt is a good idea.

    TESCO PERFORMANCE 06:30: Radio 5 live

    Tesco is struggling to compete with the likes of Aldi and Lidl because the smaller supermarkets stock fewer lines and focus on keeping prices low. "Tesco are giving people far too many reasons to go elsewhere," Steve Dresser, retail analyst, tells Wake up to Money.

    TESCO'S NEXT MOVE 06:27: BBC Radio 4

    Tesco's new boss, Dave Lewis, starts work today at the beleaguered supermarket chain, and Holly Cook, of the investment site Morningstar, tells Today that his first move may be to slash prices. Tesco, she says, "used to be a value proposition," but is now "not that much cheaper" than its rivals.

    EU REVOLT 06:20:

    In its main front page story, the Independent says David Cameron is facing a damaging new revolt over Europe. It says up to 100 Conservative MPs are planning to defy him by declaring that they'll vote to leave the EU - regardless of what concessions he wins for Britain.

    NETWORK RAIL 06:17: Radio 5 live

    Philip Haigh, railway writer, is still on Wake up to Money. Why is Network Rail in £33bn of debt? It's been spending lots of late, he says. Railway stations, for example, have never looked better. "You just have to look at King's Cross and see what they've done there," he says.

    BORIS TAKES OFF 06:14:

    Boris's comments come as we await news on whether the Airports Commission will put his favoured plan for a Thames estuary airport back onto its shortlist of options. Incidentally, Mr Johnson is seeking nomination as the Conservative parliamentary candidate in Uxbridge and South Ruislip - where Heathrow expansion is widely opposed.

    BORIS TAKES OFF 06:07:
    Plane over Heathrow

    The Telegraph carries a piece by the Mayor of London, Boris Johnson, in which he warns that expanding Heathrow, and ditching his plan for a new airport in the Thames estuary, would be a "disaster". But Mr Johnson, who has previously called for the closure of Heathrow, now suggests it could remain open as a secondary airport.

    NETWORK RAIL 06:03: Radio 5 live

    Philip Haigh, railway writer, is on Wake up to Money, talking about Network Rail's move to the government's balance sheet. On the one hand, he says, it means the state-owned company can borrow more cheaply from the government, but the government will also be able to appoint directors and intervene in things like executive pay.

    06:01: Howard Mustoe Business reporter

    Morning! Get in touch via email or via Twitter @BBCBusiness

    06:00: Joe Miller Business Reporter

    Good morning. It's a good day for current account holders - particularly those who have experienced the maddening misfortune of being charged for going overdrawn by a few pennies. Banks will now have to give customers until 2pm to cover funds before slapping on a levy. Stay tuned for reaction to that news, and the rest of the business headlines.



  • Polish and British flags alongside British roadsideWar debt

    Does the UK still feel a sense of obligation towards Poles?

  • Alana Saarinen at pianoMum Dad and Mum

    The girl who has three biological parents

  • Islamic State fighters parade in Raqqa, Syria (30 June 2014)Who backs IS?

    Where Islamic State finds support to become a formidable force

  • Spanish volunteer Rafa Munoz Perez practising with a rifle in Donetsk, 7 August Motley crew

    The Europeans who pitch up in Ukraine to join the fight

From BBC Capital


  • Volcanic eruptionThe Travel Show Watch

    Uncovering the secrets of the Icelandic island buried by a volcanic eruption

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.